Insider Transactions in Q2 2023 at Cano Health, Inc. (CANO)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
David J Armstrong |
BUY
Grant, award, or other acquisition
|
Direct |
7,506
+1.12%
|
$0
$0.77 P/Share
|
|
Jun 29
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
400,000
-24.78%
|
$400,000
$1.31 P/Share
|
|
Jun 28
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
150,000
-8.5%
|
$150,000
$1.22 P/Share
|
|
Jun 26
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Conversion of derivative security
|
Direct |
550,000
+23.77%
|
-
|
|
Jun 15
2023
|
Jacqueline Guichelaar Director |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Angel L Morales |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Alan Muney |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Kim M Rivera |
BUY
Grant, award, or other acquisition
|
Direct |
185,598
+42.75%
|
-
|
|
Jun 15
2023
|
Solomon D Trujillo |
BUY
Grant, award, or other acquisition
|
Direct |
211,581
+35.87%
|
-
|
|
Jun 12
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
500,000
-29.17%
|
$500,000
$1.42 P/Share
|
|
Jun 09
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-5.51%
|
$100,000
$1.38 P/Share
|
|
Jun 08
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
275,940
-13.2%
|
$275,940
$1.29 P/Share
|
|
Jun 08
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Bona fide gift
|
Direct |
600,000
+22.31%
|
-
|
|
Jun 08
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Bona fide gift
|
Indirect |
600,000
-100.0%
|
-
|
|
Jun 07
2023
|
Richard Aguilar Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
400,000
-21.16%
|
$400,000
$1.32 P/Share
|
|
Jun 06
2023
|
David J Armstrong |
SELL
Open market or private sale
|
Direct |
3,163
-0.48%
|
$3,163
$1.38 P/Share
|
|
May 31
2023
|
Mark Novell Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,502
+20.68%
|
-
|
|
May 31
2023
|
David J Armstrong |
BUY
Grant, award, or other acquisition
|
Direct |
109,526
+14.24%
|
-
|
|
May 31
2023
|
Marlow Hernandez |
BUY
Grant, award, or other acquisition
|
Direct |
671,742
+12.5%
|
-
|
|
May 31
2023
|
Brian D Koppy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
248,226
+19.11%
|
-
|
|
May 31
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
231,008
+15.99%
|
-
|
|
May 31
2023
|
Robert Camerlinck Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
239,139
+0.88%
|
-
|
|
May 25
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Conversion of derivative security
|
Indirect |
600,000
+50.0%
|
-
|
|
May 25
2023
|
Richard Aguilar Chief Clinical Officer |
BUY
Conversion of derivative security
|
Direct |
675,940
+26.34%
|
-
|
|
Apr 11
2023
|
Mark Novell Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,684
+23.15%
|
-
|
|
Apr 05
2023
|
Robert Camerlinck Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
2,836,540
+9.59%
|
-
|
|
Apr 05
2023
|
Brian D Koppy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
23,591
-2.86%
|
$23,591
$1.27 P/Share
|